Sector ledger
Healthcare & Pharma/Biotech Stocks: Insider Trading and Market Alerts
Every alert InsiderWatch has sent and scored in the healthcare & pharma/biotech sector: insider buys, stake filings, policy moves and market events, with the stocks involved and how each call turned out. Listed only after the outcome is known, misses included.
191
Scored alerts
147
Stocks
69%
Hit rate (n=98)
Every scored healthcare & pharma/biotech call our rules make, since the record began, misses included; measured on daily closes. Method and exclusions on the methodology page.
Stocks with healthcare & pharma/biotech alerts
- $MRK×6
- $ARTV×5
- $BRVE×5
- $NVO×5
- $SMMT×5
- $ABBV×4
- $AZN×4
- $NVS×4
- $PFE×4
- $AMGN×3
- $ATTO×3
- $BSX×3
- $ELAN×3
- $IONS×3
- $LLY×3
- $ABCL×2
- $ABVX×2
- $AHCO×2
- $ALMS×2
- $AMRX×2
- $BNTX×2
- $FULC×2
- $GILD×2
- $GSK×2
- $HIMS×2
- $LBRX×2
- $LTGO×2
- $MRNA×2
- $NGNE×2
- $NVCT×2
- $PLSE×2
- $PRQR×2
- $PRTA×2
- $TAK×2
- $TARS×2
- $TYRA×2
- $ABT
- $ABUS
- $ACB
- $ADPT
- $ALC
- $ANRO
- $APMD
- $ASND
- $ATEC
- $AURA
- $AVTX
- $BFLY
- $BLSM
- $BMRN
- $BMY
- $BOLD
- $BRTX
- $CAH
- $CAPR
- $CBIO
- $CCRN
- $CELC
- $CGON
- $CHCT
Latest scored healthcare & pharma/biotech alerts
The 25 most recent. The move is the stock’s close-to-close change over the alert’s grading window; a hit means the call’s direction was right.
| Date | Stock | Alert | Call | Result |
|---|---|---|---|---|
| Sep 16, 2026 | $HALO | Halozyme to sell $1.05B convertible notesOffering / dilution | BEARISH | MISS +6.1% |
| Sep 14, 2026 | $TYRA | Tyra prices $400M stock offering, diluting holdersOffering / dilution | BEARISH | MISS +12.2% |
| Sep 14, 2026 | $BNTX | BioNTech drug nearly doubles lung cancer survivalMarket event | BULLISH | MISS -2.8% |
| Sep 13, 2026 | $ONC | Tam-Peli Phase III lung cancer trial hits survival winMarket event | BULLISH | HIT +2.4% |
| Sep 13, 2026 | $GILD | Gilead's Trodelvy misses endpoints in Phase 3 lung cancer trialMarket event | BEARISH | MISS +2.9% |
| Sep 13, 2026 | $SMMT | Summit's ivonescimab beats Keytruda on survival in lung cancerMarket event | BULLISH | MISS -2.3% |
| Sep 11, 2026 | $NVO | Morgan Stanley cuts Novo Nordisk to SellMarket event | BEARISH | HIT -3.2% |
| Sep 11, 2026 | $ABBV | AbbVie's atogepant wins late-stage menstrual migraine trialMarket event | BULLISH | HIT +2.4% |
| Sep 10, 2026 | $ATEC | Alphatec CEO buys $1M of company stockInsider buy | BULLISH | HIT +19.7% |
| Sep 10, 2026 | $BRVE | OrbiMed cuts Braveheart Bio stake to 13.5%Activist stake | BEARISH | HIT -2.0% |
| Sep 10, 2026 | $ABBV | AbbVie's atogepant hits in menstrual migraine trialMarket event | BULLISH | HIT +3.6% |
| Sep 9, 2026 | $ALMS | Alumis director buys $10.7M after trial-miss selloffInsider buy | BULLISH | MISS -20.7% |
| Sep 9, 2026 | $AZN | AstraZeneca COPD data support Citi's $7B sales caseMarket event | BULLISH | HIT +1.1% |
| Sep 9, 2026 | $BMRN | BioMarin's VOXZOGO hits Phase 3 goals in hypochondroplasiaMarket event | BULLISH | HIT +2.1% |
| Sep 8, 2026 | $SMMT | Summit's ivonescimab beats Keytruda on survival in Phase 3Market event | BULLISH | MISS -2.6% |
| Sep 8, 2026 | $EIKN | Column Group opens $1M Eikon Therapeutics stakeInsider buy | BULLISH | MISS -20.5% |
| Sep 8, 2026 | $PRVA | Puma Growth takes 5.1% stake in Privia HealthActivist stake | BULLISH | MISS -1.9% |
| Sep 8, 2026 | $NVO | Novo Nordisk semaglutide hits goal in pediatric obesity trialMarket event | BULLISH | MISS -3.3% |
| Sep 8, 2026 | $ABT | Abbott wins FDA approval for new ablation catheterMarket event | BULLISH | MISS -3.8% |
| Sep 8, 2026 | $BSX | Boston Scientific discloses material cybersecurity incidentMarket event | BEARISH | HIT -5.4% |
| Sep 8, 2026 | $NVS | Novartis Lp(a) drug fails, clouding rival cholesterol programsMarket event | BEARISH | HIT -15.5% |
| Sep 7, 2026 | $BNTX | BioNTech halts mid-stage cancer vaccine trialMarket event | BEARISH | HIT -4.9% |
| Sep 7, 2026 | $AZN | AstraZeneca wins FDA nod for breast cancer drug EtcamahMarket event | BULLISH | MISS -2.7% |
| Sep 7, 2026 | $NVO | Novo Nordisk semaglutide hits Phase 3 goal in young childrenMarket event | BULLISH | MISS -3.0% |
| Sep 5, 2026 | $NVS | Novartis heart-drug trial disappoints in key readoutMarket event | BEARISH | HIT -15.5% |
Get Healthcare & Pharma/Biotech Alerts the Minute They Fire
Watchlist members pick up to 10 stocks; Pro members get the whole market. Email and Telegram, graded in public.
See plans7-day free trial. Cancel in one click.
Sector tags are assigned per alert by the analysis step, so a stock can appear in more than one sector. Hypothetical, close-to-close, fees excluded. Not investment advice. Full ledger on the track record.